PDC, supported by Vance Street Capital, has finalized its acquisition of Resenex to provide fluid management solutions focused on supporting the development and production needs of the healthcare and biotechnology sectors.
 
This acquisition enhances PDC’s capabilities to deliver advanced, reliable, and scalable solutions, reinforcing its commitment to providing exceptional customer value and staying at the forefront of industry innovation.
 
“We are delighted to welcome Resenex to the PDC family,” said Jeff Kyle, CEO of PDC. “This acquisition aligns perfectly with our commitment to innovation and excellence across diverse health, science, and technology markets. By combining PDC’s expertise in precision injection molding, in-house tool design and build, and value-added assembly with Resenex’s innovative product portfolio, we will further enhance our ability to provide high-quality solutions to our customers and accelerate growth in adjacent markets.”
 
“PDC’s strong commitment to quality, innovation, and customer service aligns perfectly with the values that have guided Resenex since its founding. This acquisition will allow Resenex’s products and capabilities to reach new heights, and I look forward to seeing continued growth and success,” said Shefali Parikh, former COO.
 
“We are thrilled to support PDC in this strategic acquisition,” said Steve Sandbo, Partner at Vance Street Capital. “Resenex has a strong reputation for quality and innovation in fluid flow products, which will enhance PDC’s capabilities and expand its product offerings. By merging Resenex’s innovative product line with PDC’s expertise in injection molding, we are poised to respond quickly to the evolving market demands and drive growth in new areas. This partnership creates significant expansion opportunities and reinforces PDC’s position as a leading provider of advanced micro molding manufacturing solutions across healthcare and biotechnology markets.”

Other Pharma Industry Acquisitions